Mizuho Markets Americas LLC Buys 54,871 Shares of Halozyme Therapeutics, Inc. $HALO

Mizuho Markets Americas LLC lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4.3% during the first quarter, HoldingsChannel reports. The firm owned 1,323,544 shares of the biopharmaceutical company’s stock after acquiring an additional 54,871 shares during the quarter. Halozyme Therapeutics makes up 2.3% of Mizuho Markets Americas LLC’s investment portfolio, making the stock its 10th largest position. Mizuho Markets Americas LLC’s holdings in Halozyme Therapeutics were worth $85,541,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently made changes to their positions in the company. Measured Wealth Private Client Group LLC raised its position in Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 124 shares in the last quarter. Larson Financial Group LLC grew its position in shares of Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 343 shares during the period. Harbour Investments Inc. increased its stake in shares of Halozyme Therapeutics by 152.5% during the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 372 shares during the last quarter. Clearstead Advisors LLC raised its holdings in shares of Halozyme Therapeutics by 64.8% in the 4th quarter. Clearstead Advisors LLC now owns 842 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 331 shares during the period. Finally, Wexford Capital LP bought a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at about $70,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 1,923 shares of the company’s stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $79.77, for a total value of $153,397.71. Following the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $61,245,810.60. This represents a 0.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the transaction, the director owned 14,462 shares in the company, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 74,102 shares of company stock worth $5,205,798 over the last quarter. Company insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $80.84 on Friday. The stock has a market cap of $9.59 billion, a PE ratio of 29.08, a P/E/G ratio of 0.32 and a beta of 0.84. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. The firm has a 50-day moving average of $72.79 and a 200-day moving average of $70.50. Halozyme Therapeutics, Inc. has a 52-week low of $57.67 and a 52-week high of $82.26.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. The business had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. Halozyme Therapeutics’s quarterly revenue was up 42.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on HALO. HC Wainwright reiterated a “buy” rating and set a $95.00 price target on shares of Halozyme Therapeutics in a report on Tuesday. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday. Morgan Stanley cut their price objective on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Finally, UBS Group reissued a “buy” rating and set a $90.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $81.60.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.